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Introduction: The aim of this study was to investigate PD-1/PD-L1 involvement in the hyporesponsiveness of
rheumatoid arthritis (RA) synovial fluid (SF) CD4 T cells upon stimulation by thymic stromal lymphopoietin
(TSLP)–primed CD1c myeloid dendritic cells (mDCs).
Methods: Expression of PD-1 on naïve (Tn), central memory (Tcm) and effector memory (Tem) CD4 T cell subsets
was assessed by flow cytometry. PD-L1 expression and its regulation upon TSLP stimulation of mDCs from
peripheral blood (PB) and SF of RA patients were investigated by quantitative RT-PCR and flow cytometry. The
involvement of PD-1/PD-L1 interactions in SF T cell hyporesponsiveness upon (TSLP-primed) mDC activation was
determined by cell culture in the presence of PD-1 blocking antibodies, with or without interleukin 7 (IL-7) as a
recognized suppressor of PD-1 expression.
Results: PD-1 expression was increased on CD4 T cells derived from SF compared with PB of RA patients. TSLP
increased PD-L1 mRNA expression in both PB and SF mDCs. PD-L1 protein expression was increased on SF mDCs
compared with PB mDCs and was associated with T cell hyporesponsiveness. Blockade of PD-1, as well as IL-7
stimulation, during cocultures of memory T cells and (TSLP-primed) mDCs from RA patients significantly recovered
T cell proliferation.
Conclusion: SF T cell hyporesponsiveness upon (TSLP-primed) mDC stimulation in RA joints is partially dependent on
PD-1/PD-L1 interactions, as PD-1 and PD-L1 are both highly expressed on SF T cells and mDCs, respectively, and inhibiting
PD-1 availability restores T cell proliferation. The potential of IL-7 to robustly reverse this hyporesponsiveness suggests that
such proinflammatory cytokines in RA joints strongly contribute to memory T cell activation.Introduction
Rheumatoid arthritis (RA) is characterised by progressive
joint inflammation that results in tissue damage [1]. This
is strongly dependent on CD4 T cell production of Th1
(interferon γ) and Th17 cytokines (interleukin 17 (IL-17))
[2-5]. Activation and differentiation of CD4 T cells to be-
come Th1 or Th17 cells is strongly regulated by antigen-
presenting cells such as dendritic cells (DCs) [6]. Several
types of DCs are known to circulate in human blood. They
are characterised by high expression of human leucocyte* Correspondence: f.m.moret@umcutrecht.nl; j.vanroon@umcutrecht.nl
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unless otherwise stated.antigen (HLA) class II molecules and the absence of
lineage markers (CD3, CD19, CD14, CD20, CD56 and gly-
cophorin A). Human blood DCs can be divided into at
least three subtypes (plasmacytoid DCs and two types of
myeloid or classical DCs (mDC1 and mDC2)) [7,8], based
on the blood-derived DC antigen (BDCA) molecules
[9,10]. BDCA-1 (CD1c) identifies the mDC1 subset, which
comprises potent activators of CD4 T cells, whereas
mDC2 cells, identified by expression of BDCA-3 (CD141),
more potently activate CD8 T cells [7,9,10]. In this respect,
it is important to note that the characterisation of mDC1
cells by CD1c is more specific than the previously used
and more broadly expressed marker, CD11c [7,9]. CD1c
mDCs are abundantly present in joints of RA patients,
and these synovial fluid (SF)–derived mDCs have recentlytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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to activate autologous peripheral blood (PB)–derived CD4
T cells [11].
Thymic stromal lymphopoietin (TSLP) has recently
been considered as a potential trigger to activate CD1c
mDCs in the joints of RA patients. TSLP cytokine levels
are significantly increased in the SF of RA patients com-
pared with SF of osteoarthritis patients [12,13]. TSLP has
been demonstrated to potently activate TSLPR-expressing
CD1c mDCs from SF to secrete enhanced levels of T cell–
attracting chemokines and to strongly activate PB-derived
CD4 T cells to induce Th1, Th17 and Th2 activity [13]. In
addition, recently, TSLP and its receptor were also shown
to enhance Th1- and Th17-mediated experimental arth-
ritis and tissue destruction [14].
Because of the prominent role of CD4 T cells in ar-
thritic processes and the potential of SF-derived mDCs
and TSLP-primed mDCs to activate autologous PB-
derived CD4 T cells, in this study we investigated the po-
tential of these mDCs to activate autologous SF-derived
CD4 T cells. An evident hyporesponsiveness of SF-
derived CD4 T cells upon mDC or TSLP-primed mDC
activation was observed. Several observations led us to
investigate the role of programmed death 1 (PD-1) and
its ligand interactions in this hyporesponsiveness, be-
cause ligation of PD-1 by PD-L1 or PD-L2 leads to in-
hibition of T cell proliferation [15,16]. First, our analysis
of the gene expression profiles of TSLP-primed mDCs
from RA patients revealed significant upregulation of
PD-L1 and much higher expression levels compared with
PD-L2. In addition, preliminary data had shown us that
PD-L1 was upregulated on SF mDCs of RA patients. Third,
data from previous studies [17] and ours indicated overex-
pression of PD-1 on synovial CD4 T cells of RA patients.
Because IL-7 recently was shown to downregulate PD-1 ex-
pression on T cells [18] and because of the potent T cell
stimulatory capacity of IL-7 [19], we also examined the role
of IL-7 in the regulation of PD-1/PD-L interactions in hy-
poresponsiveness of synovial T cells. Our data demonstrate
that hyporesponsiveness of synovial CD4 Tcells in response
to SF-derived CD1c mDCs is dependent on PD-1/PD-L1
interactions and is robustly reversed by IL-7.
Methods
Patients
SF was obtained from 13 RA patients during effusion of
the knee and 70 ml of heparinized PB was collected
from 16 RA patients. RA was classified according to the
American College of Rheumatology criteria [20]. Ethical
approval for this study was granted by the medical ethics
committee of the University Medical Center Utrecht for
the collection of patient samples in compliance with the
Helsinki Declaration. All patients gave their written in-
formed consent to participate.Cell isolation
Mononuclear cells (MNCs) were isolated from PB and
SF by density centrifugation using Ficoll-Paque Plus (GE
Healthcare, Uppsala, Sweden). Prior to MNC isolation,
PB or SF was diluted 1:1 with RPMI 1640 medium
(Gibco/Life Technologies, Grand Island, NY, USA) con-
taining penicillin (100 U/ml), streptomycin (100 μg/ml)
and glutamine (2 mM) (all from PAA Laboratories,
Pasching, Austria). PB- and SF-derived CD1c mDCs and
CD4 T cells were isolated from the MNC fraction by
magnetic-activated cell sorting (MACS) using CD1c
(BDCA-1)-positive dendritic cell and CD4+ T cell isola-
tion kits (Miltenyi Biotec, Bergisch Gladbach, Germany).
PB memory T cells were isolated from the CD4 T cell
fraction by their lack of CD45RA expression using the
CD45RA+ isolation kit (Miltenyi Biotec). Isolations were
performed according to the manufacturer’s instructions.
Cell cultures
All cells were cultured in RPMI GlutaMAX medium
(Gibco/Life Technologies) supplemented with penicillin,
streptomycin and 10% (vol/vol) GemCell human serum AB
(Gemini Bio-Products, West Sacramento, CA, USA). The
mDCs were cultured at a cell concentration of 0.5 × 106
cells/ml with or without recombinant TSLP at 20 ng/ml
(R&D Systems, Minneapolis, MN, USA) for 20 hours in
Sarstedt tubes (Sarstedt, Nümbrecht, Germany) at 37°C.
The functional capacities of PB- and SF-derived mDCs
were assessed by measuring activation of autologous
CD4 T cells derived from PB and SF. For this purpose,
isolated T cells were seeded in round-bottomed 96-well
plates at a concentration of 0.25 × 106 cells/ml and kept
at 37°C in full culture medium before coculturing with
the (TSLP-primed) mDCs. Washed TSLP-activated mDCs
and unstimulated mDCs were added to the autologous T
cells (mDC:T cell ratio 1:5 or 1:10) in triplicate in the ab-
sence of additional stimuli and cocultured for 6 days. To
test the effects of PD-1 blockade or IL-7 effects in cocul-
tures of mDCs and memory T cells from PB and SF, anti-
PD-1 mAB (1 μg/ml; BioLegend, San Diego, CA, USA) or
IL-7 (10 ng/ml, PeproTech, Rocky Hill, NJ, USA) was
added at the start of the cocultures. Proliferation was mea-
sured by [3H]thymidine incorporation (1 μCi/well added
during the last 18 hours of a culture period; PerkinElmer,
Waltham, MA, USA).
Flow cytometry
PD-1 expression on CD4 T cells and PD-L1 expression on
CD1c mDCs of RA patients were analysed by flow cytome-
try using a FACSCanto II flow cytometer (BD Biosciences,
San Jose, CA, USA). Ex vivo or cultured mDCs were stained
with CD1c phycoerythrin (CD1c-PE; BD Biosciences),
CD19 peridinin chlorophyll (CD19-PerCP; BioLegend) and
CD274 (PD-L1)-APC (BioLegend). mDCs were gated as
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were stained with CD45RO fluorescein isothiocyanate
(CD45RO-FITC; Dako, Glostrup, Denmark), CD27-
APC (Invitrogen), CD279 (PD-1)-PE and CD4-PerCP
(BioLegend) using isotype antibodies or autofluorescence
as controls. All samples were analysed using FlowJo soft-
ware (TreeStar, Ashland, OR, USA). To compare mean
fluorescence intensity (MFI) values, the autofluorescence
intensity was subtracted from the MFI of the stains to re-
veal true expression values.
Real-time quantitative RT-PCR
To examine TSLP-mediated PD-L1 gene regulation in
isolated CD1c mDCs from PB and SF of RA patients,
CD1c mDCs (0.5 × 106 cells/ml) were stimulated with
20 ng/ml recombinant TSLP (R&D Systems) or left un-
treated for 20 hours in Sarstedt tubes at 37°C. mDCs
were collected and lysed in Buffer RLT (QIAGEN, Carpin-
teria, CA, USA) prior to RNA isolation. Total RNA was
isolated using the RNeasy Mini Kit (QIAGEN) according
to the manufacturer’s instructions. RNA quantity was mea-
sured by using a NanoDrop spectrophotometer (Nano-
Drop Technologies, Wilmington, DE, USA), and RNA
quality was assessed on a 2100 Bioanalyzer (Agilent Tech-
nologies, Santa Clara CA, USA). cDNA synthesis was per-
formed with an automated system (Caliper Life Sciences
NV/SA, Teralfene, Belgium), starting with 70 ng of total
RNA from each sample, as previously described in detail
[21]. Gene expression was quantified by quantitative RT-
PCR (RT-qPCR) performed in duplicate from 3 ng of
cDNA in the presence of SYBR Select Master Mix (Life
Technologies, Carlsbad, CA, USA) and 1.5 μM of specific
primer pairs (PD-L1 forward: 5′-GCT GAA CGC ATT
TAC TGT CAC-3′, PD-L1 reverse: 5′-TGT TCT TAT
CCT CCA TTT CCC A-3′; GAPDH forward: 5′-ATG
GGG AAG GTG AAG GTC G-3′, GAPDH reverse: 5′-
GGG GTC ATT GAT GGC AAC AAT A-3′). The ana-
lyses were performed using the QuantStudio 12K Flex
system (Life Technologies) with the following thermal cycle
conditions: 95°C for 20 seconds, followed by 40 cycles of
95°C for 1 second and 60°C for 20 seconds. Gene expres-
sion values were calculated according to the comparative
threshold cycle method [22] using the stably expressed
GAPDH as an endogenous control. The value of each con-
trol sample was set at 1 and was used to calculate the fold
change in target mRNA.
Statistical analysis
Differences between conditions were assessed by paired-
samples evaluation using the nonparametric Wilcoxon
signed-rank test unless indicated otherwise. Unpaired
data analysis was performed using the nonparametric
Mann–Whitney U test. Data analysis was performed
using SPSS software version 20.0 (SPSS, Chicago, IL,USA). Data were considered statistically significant at
P < 0.05.
Results
Synovial CD4 T cells from RA patients are hyporesponsive
to stimulation by (TSLP-primed) CD1c mDCs
Myeloid DCs derived from SF of RA patients have a
strong capacity to activate autologous PB-derived CD4 T
cells (Figure 1A) [11]. In addition, TSLP-primed mDCs
(TSLP-mDCs) from PB and SF strongly activate PB-
derived T cells (Figure 1A) [13]. Whereas PB-derived
CD4 T cells are strongly activated by TSLP-mDCs
(Figures 1A and 1B), SF-derived CD4 T cells were hardly
responsive to these in vivo and in vitro activated mDCs
(Figures 1A and 1C).
Several recent observations by others and us indicated
that programmed death-1 (PD-1)/PD ligand 1 (PD-L1)
interactions could play a role in the regulation of syn-
ovial T cell hyporesponsiveness to (TSLP-primed) mDCs
from RA patients. First, microarray analysis had shown
that PD-L1 mRNA was highly expressed compared with
PD-L2 mRNA expression and significantly upregulated
upon TSLP activation in addition to upregulated costi-
mulatory and antigen-presenting molecules such as
CD80, CD86, HLA class II and CD1c (data not shown).
In addition, preliminary data had shown us that PD-L1
was upregulated on SF mDCs of RA patients. Therefore,
we set out to investigate the expression levels of PD-1
on T cells, PD-L1 on mDCs from PB and SF of RA pa-
tients and the capacity that this interaction has to regu-
late T cell responsiveness.
Memory CD4 T cells from synovial fluid express robustly
increased PD-1 levels
CD4 T cell subsets can be divided into naïve, central
memory and effector memory T cells (Tn, Tcm and Tem
cells, respectively), based on the expression of CD27 and
CD45RO. In RA patients, PB-derived T cells consist
mainly of naïve and central memory T cells, whereas
SF-derived T cells hardly contain any naïve T cells and
consist mainly of central memory and effector memory
T cells (Figure 2A). Because SF memory T cell hypore-
sponsiveness upon TSLP-mDC stimulation can be
caused by enhanced expression of PD-1 interactions, we
measured the expression of this inhibitory receptor on
the CD4 T cell subsets derived from PB and SF of RA
patients (Figure 2B, representative histograms). Naïve T
cells from PB and SF expressed the lowest levels of
PD-1, although naïve CD4 T cells from SF had strongly
upregulated levels of PD-1 compared with naïve CD4
T cells from PB (Figure 2C). However, considering the
different expression levels of CD45RO on these ‘naïve’
SF T cells compared to those from PB, we are reluctant
to characterise these cells as ‘naïve’ (Figure 2A). Mainly
Figure 1 CD4 T cells derived from synovial fluid of rheumatoid arthritis patients are hyporesponsive upon (TSLP-primed) myeloid
dendritic cell stimulation in contrast to peripheral blood-derived CD4 T cells. Thymic stromal lymphopoietin (TSLP)-primed myeloid
dendritic cells (mDCs) from peripheral blood (PB) as well as both mDCs and TSLP-primed mDCs from synovial fluid (SF) of rheumatoid arthritis
(RA) patients strongly activate PB-derived CD4 T cells, whereas SF-derived CD4 T cells are hyporesponsive upon (TSLP-primed) mDC activation.
(A) mDC:T cell ratio 1:5, paired analysis of CD4 T cells and mDCs of a representative donor are shown. (B) mDC:T cell ratio 1:10 derived from PB of five
RA patients. (C) mDC:T cell ratio 1:10 derived from SF of five RA patients. *P < 0.05 (statistically significant difference). CPM, counts per minute.
Figure 2 Memory CD4 T cells, in particular synovial fluid–derived T cell subsets, express increased PD-1 levels. (A) CD4 T cells derived
from synovial fluid (SF) of rheumatoid arthritis (RA) patients hardly contain any naïve T (Tn) cells and (B) express increased PD-1 levels. Representa-
tive histogram of PD-1 expression on PB and SF CD4 T cells of one donor is shown. Dashed line represents autofluorescence. (C) PD-1 expression is
increased on central memory (Tcm) and effector memory (Tem) T cells in comparison with naïve T cells (Tn cells) from peripheral blood
(PB; n= 9, both P < 0.01) and SF (n = 7, both P < 0.05). PD-1 expression was strongly upregulated on all CD4 T cell subsets derived from SF versus PB of
RA patients. *P < 0.05, **P < 0.01 and ***P < 0.001 (statistically significant differences). MFI, mean fluorescence intensity; PD-1, Programmed death 1.
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creased percentage of Tcm and Tem cells from SF
expressed PD-1 compared with those from PB (Figure 2C).
PD-L1 is upregulated by TSLP and highly expressed on
synovial fluid CD1c mDCs
Confirming microarray data, TSLP significantly up-
regulated the mRNA expression of PD-L1 in PB- and
SF-derived mDCs (Figure 3A), showing much higher
expression levels of PD-L1 mRNA expression com-
pared with PD-L2 (data not shown). The PD-L1 mRNA
upregulation upon TSLP stimulation of mDCs was
confirmed by an increased PD-L1 surface expression
(Figure 3B). To confirm our RNA data, we assessed
the ex vivo PD-L1 protein expression on CD1c
mDCs from PB and SF of RA patients (Figure 3C).
The number of mDCs expressing PD-L1 was signifi-
cantly increased in SF compared with PB, and mDCs
derived from SF had a higher intensity of PD-L1
expression compared with mDCs derived from PB
(Figure 3D).
TSLP-mDC driven memory T cell hyporesponsiveness is
partially dependent on PD-1/PD-L1 interactions
Next, we examined whether the hyporesponsiveness of
SF memory CD4 T cells was caused by their increasedFigure 3 PD-L1 is upregulated by TSLP and highly expressed on syno
(TSLP) stimulation of myeloid dendritic cells (mDCs) significantly upregulates
fluid (SF)–derived mDCs of rheumatoid arthritis (RA) patients; circles represen
and (B) PD-L1 protein expression. Representative histrogram of PD-L1 expres
mDCs (transparent) from PB of one donor is shown. Dashed line represents
CD1c mDCs derived from SF (n= 8) compared with PB (n= 9) of RA patien
(filled light grey area; solid line) and SF mDCs (transparent area; solid line) of on
(filled light grey area) and SF mDCs (transparent). (D) Mean percentages and M
*P< 0.05, **P< 0.01, and ***P< 0.001 (statistically significant differences). MFI, Meexpression of PD-1 in combination with the increased
PD-L1 expression on SF-derived mDCs. For this pur-
pose, we cocultured memory CD4 T cells derived from
either PB or SF of RA patients with TSLP-activated
mDC from PB or SF, respectively, in the presence and
absence of PD-1 blocking antibodies. Both memory CD4
T cells from PB and SF showed a similar reduced
capacity to respond to TSLP-activated mDCs (data not
shown). Blocking PD-1 interactions in cocultures of
memory T cells activated by mDCs resulted in a signifi-
cant increase of the T cell proliferation (Figure 4A).
Stimulation of mDCs by TSLP resulted in upregulated
memory T cell proliferation, which was also elevated by
blocking PD-1 ligation (Figure 4A).
Previously, it has been demonstrated that synovial
CD4 T cells are hyperresponsive to IL-7 and that IL-7
has the capacity to downregulate PD-1 expression
[18,19]. Therefore, using another way to regulate PD-1
signalling, we assessed the functional consequence of
adding IL-7. IL-7 strongly enhanced memory T cell pro-
liferation activated by mDCs or TSLP-mDCs. However,
although we observed that IL-7 inhibited PD-1 expres-
sion after 20 hours, PD-1 downregulation was apparently
not complete, as IL-7-induced T cell proliferation was
further enhanced upon prevention of PD-1 signalling by
PD-1-blocking antibodies (Figure 4B).vial CD1c myeloid dendritic cells. (A) Thymic stromal lymphopoietin
PD-L1 mRNA expression (peripheral blood (PB)–derived and synovial
t unstimulated mDCs, squares represent TSLP-stimulated mDCs, n= 5)
sion on TSLP-stimulated mDCs (filled dark grey area) and unstimulated
autofluorescence. (C, D) PD-L1 is expressed to a higher extent on
ts. (C) Representative histogram of PD-L1 expression on PB mDCs
e donor is shown. Dashed line represents autofluorescence for PB mDCs
FI of PD-L1 expression of PB and SF mDCs (n= 9 and n= 8, respectively).
an fluorescence intensity; PD-L1, Programmed death ligand 1.
Figure 4 Hyporesponsiveness of memory CD4 T cells from rheumatoid arthritis patients upon TSLP-primed myeloid dendritic cell
stimulation is at least partially reversed by PD-1 blockade. (A) Blockade of PD-1/PD-L1 interactions by anti-PD-1 antibody (1 μg/ml) in
(TSLP-primed) myeloid dendritic cell (mDC) driven memory CD4 T cell activation from peripheral blood (PB) (n = 4, filled symbols) and synovial
fluid (SF) (n = 4, open symbols) partially restores the T cell proliferative capacity. (B) Memory CD4 T cell hyporesponsiveness from SF (n = 4) is
strongly reversed by interleukin-7 (IL-7), a cytokine that largely downregulates PD-1. Additional PD-1 blockade by anti-PD-1 antibody further
reversed the downregulated proliferation. Statistical differences between these conditions were assessed using the paired-samples t-test. *P < 0.05
(statistically significant difference). PD-1, Programmed death 1; PD-L1, Programmed death ligand 1; TSLP, Thymic stromal lymphopoietin.
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In the present study, we have demonstrated that, in con-
trast to CD4 T cells from PB, CD4 T cells derived from
SF are hyporesponsive upon activation by (TSLP-
primed) CD1c mDCs. SF-derived CD4 T cells consist
mainly of memory T cells, which express elevated levels
of PD-1, whereas SF-derived CD1c mDCs abundantly
express its ligand PD-L1, which is upregulated by TSLP.
Memory T cell hyporesponsiveness is partially dependent
on PD-1/PD-L1 interactions because blockade of these
interactions by anti-PD-1 antibodies partially restores
the T cell proliferation. Importantly, IL-7, an inhibitor of
PD-1 expression, also overcomes hyporesponsiveness
and robustly activates synovial memory T cells in the
context of activated (TSLP-primed) mDCs, which could
be further enhanced by blocking PD-1.
Similarly to TSLP-primed mDCs from PB, SF-derived
mDCs have a strongly enhanced capacity to activate T
cells derived from PB that is even upregulated upon
TSLP stimulation [13]. Associated with this enhanced T
cell stimulatory capacity, enhanced expression of
antigen-presenting molecules, including CD1c and HLA
class II, and costimulatory molecules, including CD80,
CD86 and CD40, have been demonstrated [11,13]. In
support of this finding, activation of PB-derived T cells
by (TSLP-primed) mDCs is strongly dependent on costi-
mulation and antigen presentation as blockade of HLA-
class II molecules or CD80/86 costimulation blocked T
cell activation [13]. However, despite the abundance of
antigen-presenting and costimulatory molecules, the ac-
tivity of T cells derived from SF of RA patients activated
by autologous (TSLP-primed) mDCs is strongly ham-
pered. Although several mechanisms might be involved
in the reduced capacity of SF-derived T cells in response
to activated mDCs, the role of PD-1/PD-L1 interactions,
which negatively regulate T cell activation [15], was in-
vestigated for obvious reasons, such as overexpression ofPD-L1 by activated mDCs from SF and high PD-L1
mRNA levels induced by TSLP. Blockade of PD-1/PD-
L1 interactions has been shown to result in increased T
cell activity [23] and PD-1 deficiency, and PD-L1 defi-
ciency is shown to play a critical role in the development
of autoimmune disorders in mice [24,25].
In line with our results showing increased PD-1 ex-
pression on SF-derived memory T cells compared with
PB-derived T cells, PD-1 expression was previously de-
scribed to be increased on SF-derived CD4 T cells [17].
These SF-derived T cells were previously suggested to
be resistant to PD-1 mediated suppression, as PD-L1
expression on SF-derived CD14+ monocytes and macro-
phages was not sufficiently high to effectively downregu-
late T cell activation [17]. In contrast to this latter
suggestion, we observed hyporesponsiveness of SF T
cells upon activation by in vivo activated synovial mDCs
and in vitro activated TSLP-mDCs, which, in contrast,
expressed high levels of PD-L1. PD-1-blocking anti-
bodies, blocking interactions with PD-L1, resulted in an
increase in the T cell proliferation, indicating that SF-
derived T cell hyporesponsiveness is at least partially
dependent on PD-1/PD-L interactions. However, based
on the strong expression of both PD-1 on T cells and
PD-L1 on activated mDCs, more robust reversal of T
cell hyporesponsiveness was expected. The lack of re-
sponse might be due to the fact that PD-1 is also
expressed on regulatory T cells, preventing immunosup-
pression by these cells [26]. Because previous studies, in-
cluding those of our group, have demonstrated an
increased presence of regulatory T cells in the SF [27],
blockade of PD-1, next to increased activation of effector
cells, might enhance the function of regulatory T cells,
resulting in a somewhat more limited reversal of T cell
inhibition. An alternative explanation is that enhanced
antigen presentation due to robust upregulation of HLA
class II by TSLP may limit the effect of PD-1 blockade,
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that the inhibitory effect of the PD-1/PD-L pathway on
CD4 T cells was greatest at lower antigen concentrations
[16,25]. Additionally, blockade of PD-L1 has been shown
to more potently restore T cell proliferation compared
with PD-1 blockade in antigen-driven T cell responses
[28]. Although not tested in the present study, this
might result in a stronger restoration of the SF-derived
T cell hyporesponsiveness.
Hyporesponsiveness of SF-derived CD4 T cells upon
mDC or TSLP-mDC stimulation was robustly reversed
by IL-7, which is in line with previous data demonstrat-
ing vigorous activation and even hyperresponsiveness of
synovial CD4 T cells in the context of monocytic cells
[19]. Recently, IL-7 was shown to prevent shutdown of
T cell activation by downregulation of PD-1 expression
[18]. We also found PD-1 downregulation upon IL-7
stimulation of CD4 T cells in the present study (data not
shown). Apart from the capacity of IL-7 to downregulate
PD-1 expression [18], IL-7 is also shown to overcome
PD-1-mediated inhibition of T cells by STAT5 activation
that is regulated by IL-2 and family members such as IL-
7 and IL-15 [29,30]. IL-7 and IL-15 are both abundantly
present in joints of RA patients [19,31], which suggests
that the inflammatory environment in RA joints could
play a critical role in overcoming PD-1-mediated inhib-
ition of T cells. Although reversing PD-1-mediated in-
hibition is likely a crucial mechanism whereby IL-7
overcomes hyporesponsiveness, other mechanisms in-
duced by IL-7 could be involved as well, such as upregu-
lation of (co)stimulatory molecules that were previously
found to be induced by IL-7, both on T cells (for ex-
ample, lymphocyte function–associated antigen and
CD69) and on myeloid cells (CD40, CD80, CD86) [19].
Conclusions
The present study demonstrates that PD-1/PD-L1 interac-
tions between SF-derived T cells and in vivo activated SF
mDCs or in vitro TSLP-primed mDCs contribute to T cell
hyporesponsiveness. The potential of IL-7 to robustly
counteract this hyporesponsiveness suggests that such
cytokines in joints of RA patients might strongly contrib-
ute to the activation of memory T cells, in addition to the
potential of SF-derived mDCs to activate autologous
peripheral (naïve) CD4 T cells attracted to the joint.
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